| abstract |
The present invention relates to Bevacizu by measuring expression levels of one or more of VEGFA, VEGFR2 and PLGF, in particular plasma expression levels, relative to control levels of patients diagnosed with breast cancer, particularly HER-2 negative breast cancers that are locally advanced, recurrent or metastatic. The addition of bevacizumab (Avastin®) to chemotherapy may improve the therapeutic effect of chemotherapy in patients with breast cancer, particularly in patients with locally advanced, recurrent, or metastatic HER-2 negative breast cancer. Provide a way to improve. In particular, the present invention provides a method of improving the therapeutic effect, wherein the therapeutic effect is progression free survival of the patient. In addition, the present invention measures expression levels of one or more of VEGFA, VEGFR2 and PLGF, in particular plasma expression levels, relative to control levels in patients diagnosed with breast cancer, particularly HER-2 negative breast cancers that are locally advanced, recurrent or metastatic. Thereby providing a method of assessing a patient's sensitivity or responsiveness to bevacizumab (Avastin®) in combination with chemotherapy. |